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ABSTRACT
Molecular characterization of drug resistance of Mycobacterium tuberculosis strains of different origins can
generate information useful for developing molecular methods that are widely applicable for rapid drug re-
sistance detection. Using DNA sequencing and allele-specific polymerase chain reaction (AS-PCR), we inves-
tigated genetic mutations associated with isoniazid (INH) and rifampin (RIF) resistance among 29 drug-re-
sistant clinical isolates of M. tuberculosis collected from Malatya, Turkey, including 19 multi-drug-resistant
(MDR) isolates. Point mutations were detected at codons 531, 516, 526, and 513 of the RNA polymerase -
subunit gene (rpoB) in 10 (47.6%), five (23.8%), three (14.3%), and three (14.3%) of the 21 RIF-resistant iso-
lates, respectively. Of the five isolates having mutations in codon 516, three also had mutations at codon 527;
one had a concurrent mutation at codon 572. Mutations at codon 315 of the catalase-peroxidase-encoding gene
(katG) were found in 17 (63.0%) of the 27 INH-resistant isolates. Interestingly, the katG codon 315 mutation
was observed at a much higher frequency in MDR isolates than in INH-mono-resistant isolates (79% vs.
25%). This study provided the first molecular characterization of INH and RIF resistance of M. tuberculosis
clinical isolates from Eastern Turkey, and extended our knowledge of molecular basis of M. tuberculosis drug
resistance.
INTRODUCTION
ISONIAZID (INH) and rifampin (RIF) are two principal primaryanti-tuberculosis drugs. M. tuberculosis resistance to INH
and RIF is a significant challenge to global tuberculosis (TB)
control.17 Multi-drug-resistance (MDR) is defined as resistance
to at least INH and RIF.10 Previous studies have found that
about 96% of epidemiologically unrelated RIF resistant isolates
have mutations in the 81-bp-core region of the rpoB gene of
M. tuberculosis that includes codons from 507 to 533, encod-
ing 27 amino acids.16 The most commonly seen mutations that
result in amino acid replacements are at codons 516, 526, and
531.2,16,21,24 For INH resistance, while mutations in several
genes of M. tuberculosis have been found to be associated with
INH resistance, mutations in the katG gene that encodes the
catalase-peroxidase enzyme have been the most commonly ob-
served ones (26–93.6%).5,9,12,16
Geographic variation may play a role in the occurrence of
some genetic mutations.7,18 Molecular characterization of re-
sistant strains isolated from different regions of the world, par-
ticularly from countries with a high incidence rate of TB and a
high prevalence of anti-TB drug resistance, will extend our
knowledge of molecular basis of M. tuberculosis drug resis-
tance, which will in turn facilitate the development of more ef-
ficient molecular methods for rapid drug resistance detec-
tion.5,16
Turkey is a resource-limited country with a high annual in-
cidence rate of TB (e.g., 25.6/100,000 in 1997 and 17.2/100,000
in 2001).25 The reported rate of resistance to at least one drug
has been 23.8–39.2% in recent years.1,3,6,8,20 However, so far,
only a limited number of studies have been carried out to char-
acterize the genetic changes associated with drug resistance of
M. tuberculosis isolates obtained from Turkey.2,19 In this re-
port, we present this first investigation to profile genetic muta-
tions associated with the RIF and INH resistance of M. tuber-
culosis clinical isolates obtained from TB patients from
Malatya, a city located in Eastern Turkey with about 850,000
inhabitants and having a TB incidence rate (32/100,000 in 2000)
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that is higher than the national average (26.6/100,000 in
2000).11 The prevalence of INH mono-resistance and MDR-TB
was 10–11% and 2.3–3.3% in 2000, respectively.3,4
MATERIALS AND METHODS
M. tuberculosis isolates
The study sample included a total of 57 M. tuberculosis iso-
lates obtained from 57 TB patients who were diagnosed at the
Inonu University Hospital and two TB control dispensaries in
Malatya, Turkey. These three facilities, all together, serve a to-
tal of about 90% of the TB patients from this region and have
diagnosed about 80–90 culture-proven TB cases each year in
the recent several years. The isolates investigated in this study
included 19 MDR, two RIF mono-resistant, and eight INH
mono-resistant, and 28 pan-sensitive isolates. These 19 MDR
isolates represented all the MDR isolates collected in the Clin-
ical Microbiology Laboratory of the Inonu University from
1996 through 2002 (two or three isolates per year). The two
RIF mono-resistant and eight INH mono-resistant isolates are
all the drug-resistant isolates identified in 2000, except for three
MDR isolates. The 28 pan sensitive isolates were randomly se-
lected from the drug-susceptible clinical isolates obtained in
2000.
Drug susceptibility testing
Drug susceptibility testing for INH and RIF was performed
by the modified proportion method in the BACTEC 460 ra-
diometric system (Becton Dickenson and Co., Sparks, MD).
Drug resistance was defined as greater than 1% growth in the
presence of 0.1 g of INH per ml and 2 g of RIF per ml.
MDR was defined as resistance to at least INH and RIF.10
DNA extraction and fingerprinting
Genomic DNA of the study isolates was extracted from
Loweinstein-Jensen culture as described previously.23 To de-
termine the clonal relatedness of the study isolates, DNA fin-
gerprinting was performed on all the isolates using the standard
IS6110 restriction fragment length analysis (RFLP), which is
also called IS6110 DNA fingerprinting.22
DNA sequencing
PCR was used to generate DNA fragments for sequencing.
For each reaction, a standard 50 l reaction mixture was used,
containing 20 pmol of each primer in 2 l, 1 l of a 50 de-
oxyribonucleotide mix, 5 l of 10 reaction buffer, 1 l of
50 BD Advantage™2 Polymerase Mix, 2 l of DNA solu-
tion containing 20 ng DNA template, and 37 l of PCR grade
water. For the molecular characterization of RIF resistance, a
249-bp central region of the rpoB gene that covers the 81-bp
core region known to be the marker for RIF resistance was am-
plified with primers ROF and RIR described previously.14 The
thermocycling parameters of PCR are as follows: an initial de-
naturing at 96°C for 3 min, 25 cycles of 95°C for 50 sec, 65°C
for 40 sec, and 72°C for 20 sec, and a final extension at 72°C
for 3 min. For the molecular characterization of INH resistance,
a 435-bp region of the katG gene that includes codon 315, the
most prevalent mutation site associated with INH resistance,
was amplified using primers katgOF and katg4R.13 The ther-
mocycling parameters of PCR included an initial denaturing at
96°C for 3 min, 25 cycles of 95°C for 50 sec, 68°C for 40 sec,
and 72°C for 1 min, and a final extension at 72°C for 10 min.
The PCR products were purified using QIAquick PCR purifi-
cation kit according to the instructions of the manufacturer 
(QIAGEN Inc., Stanford, Valencia, California). Automated se-
quencing of the double strands of the purified PCR products
was performed using Applied Biosystems DNA sequencer
(Model 3700 or 3730). Sequence data were analyzed in com-
parison with the sequence of M. tuberculosis H37Rv using soft-
ware Edit Seq 5.02 and MegAlign 5.01 (DNAStar Inc Madi-
son, Wisconsin).
AS-PCR
In parallel to DNA sequencing, we performed three AS-PCR
assays targeting codons 516, 526, and 531 of the rpoB gene,
respectively, on the RIF-resistant isolates and an AS-PCR tar-
geting codon 315 of the katG gene on the INH-resistant iso-
lates using primers described previously.13,14 For each AS-PCR,
we used two outer primers that amplify an internal control frag-
ment and one inner allele-specific primer, the 3 end of which
was positioned to pair with the second bases of the target codon
according to the wild-type sequence. Thus, when no mutation
existed in the targeted codons, the wild-type allele-specific frag-
ment was amplified by the outer primer and the inner forward
allele-specific primer. In contrast, no AS-PCR product was gen-
erated when there was a mutation at the targeted codon. The
AS-PCR patterns were visualized by 2.5% agarose gel elec-
trophoresis in 1 TBE buffer.
RESULTS
DNA fingerprinting
The clonal relatedness of the study isolates was assessed
based on their IS6110 RFLP patterns. Of the 29 resistant iso-
lates analyzed, 25 were identified as unique strains based on
their distinct RFLP patterns, and the other four isolates were
grouped into two clusters. No definite epidemiological links
was established between the two isolates in each of the two
clusters.
Findings of DNA sequencing
DNA sequencing revealed mutations at codons 531, 526,
516, and 513 of the rpoB gene in 10 (47.6%), three (14.3%),
five (23.8%), and three (14.3%) of the 21 RIF resistant iso-
lates, respectively. At a single codon, only a single nucleotide
change was observed. However, mutations at codon 516 ap-
peared to be often associated with an additional mutation at
a different codon. Of the five isolates with a mutation at
codon 516, three also had mutations at codon 527, while one
had a simultaneous mutation at codon 572 (Table 1). In con-
trast, mutations at codons 531, 526, and 513 were not asso-
ciated with any additional mutations at a different codon. No
mutation was found in any of the 21 RIF-susceptible control
isolates sequenced.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Mutation at katG codon 315 was seen in 17 (63.0%) of the
27 INH-resistant isolates analyzed. The most prevalent muta-
tion observed in this study was AGC315ACC, involving 11
(65%) of the 17 INH-resistant isolates having a mutation in the
sequenced region (Table 1). Ten INH-resistant and all 29 INH-
susceptible isolates sequenced had no mutation in this region.
Of the 19 MDR isolates, 15 (78.9%) showed a mutation in
codon 315, while only two (25%) of the eight INH mono-re-
sistant isolates were found to have a mutation in that codon.
The mutations detected in both isolates of each of the two
clusters were the same (Table 1), although no definite epi-
demiological links could be established between the clustered
cases.
Findings of AS-PCR
As shown by Figures 1 and 2, distinct banding patterns
were generated by AS-PCR for different mutation profiles.
The AS-PCR showed a 100% concordance with the se-
quencing for detection of mutations at codons 531 and 516
of the rpoB gene. As expected, all the RIF-susceptible iso-
lates yielded both the wild-type AS-PCR fragment and the
invariable 249-bp internal control fragment. In contrast, the
RIF-resistant isolates with a mutation at the targeted codons
generated only the 249-bp internal control fragment. While
evaluating the results of the AS-PCR targeting codon 516,
we found that eight isolates yielded only the 249-bp frag-
ment. Of the eight isolates, five had a mutation at codon 516,
and the remaining three had a mutation at codon 513, which
was nested in the codon 516 allele-specific primer. The three
isolates with mutations at codon 527 yielded a PCR pattern
identical to that of the isolates having mutations at codon
531, because codon 527 was nested in the allele-specific
primer for codon 531. AS-PCR targeting codon 315 of the
katG gene generated mutant type pattern for 16 of the 17 iso-
lates that were found to have a mutation at this codon by
DNA sequencing.
DISCUSSION
Our study is the first molecular characterization of INH and
RIF resistance of M. tuberculosis clinical isolates from Eastern
Turkey. Given the low level of clonal and epidemiological re-
latedness among the study isolates as indicated by the IS6110
RFLP patterns and the long time frame for the collection of the
study isolates, we consider the profile of M. tuberculosis drug
resistance–associated genetic mutations obtained from this
study to be representative for the study region. The information
generated from this study will be useful for the rational design
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FIG. 1. Sample of 2% agarose gel electrophoresis visualized results of three independent allele-specific PCR assays targeting
codons 516 (A), 526 (B), and 531 (C) of the rpoB gene, respectively. The 249-bp fragment is an internal control of the PCR that
was invariably amplified. The length of the allele-specific fragments are 167, 181, and 214 bp for codons 516, 526, and 531, re-
spectively. No wild-type allele-specific PCR fragments were generated by isolates that had a mutation in the targeted codon. (A)
Lanes 1–3, isolates with no mutations at codon 516; lane 4, isolate with codon 516 mutation. (B) Lanes 1 and 2, isolates with
codon 526 mutation; lanes 3–6, isolates with no mutation at codon 526; lane 7, reaction mix without DNA templete. (C) Lanes
1 and 2, isolates with no mutation at codon 531; lanes 3–5, isolates with codon 531 mutation; lane 6, reaction mix without DNA
templete. Lane M on each panel, 100-bp DNA ladder (Bio-Rad Laboratories, Hercules, CA).
FIG. 2. Sample of 2% agarose gel electrophoresis visualized
results of the allele-specific-PCR assay targeting codon 315 of
katG gene. When an isolate has no mutation at codon 315 of
the katG gene, a 292-bp wild-type allele-specific fragment is
expected, whereas no amplification of this wild-type allele-spe-
cific fragment will occur when there is a mutation at this codon.
Instead, the two outer primers katGOF and katg4R will amplify
a 435-bp fragment for the isolates with mutations at codon 315.
Lanes 1 and 2, isolates with no mutation at codon 315; lanes 3
and 4, isolates with codon 315 mutation; lane M, 100-bp DNA
ladder.
A B C
of molecular tests for rapid screening for INH and RIF resis-
tance–related mutations in Turkey, which will in turn contribute
to the control of MDR-TB in Turkey and worldwide.
Comparison of our results with the findings from an earlier
study conducted in Western Turkey that, like our study, also
used a convenience sample including 41 RIF-resistant isolates
from 41 different patients2 indicated the existence of regional
differences in the mutation profiles of M. tuberculosis isolates.
For example, the proportion of isolates with mutations at codons
531, 526, and 516 of rpoB were 56.1%, 19.5%, and 7.3%, re-
spectively, in the Western Turkey study, whereas in our study,
the corresponding proportions of isolates were 47.6%, 14.3%,
and 23.8%, respectively. Furthermore, we found that three
(14.3%) of the 21 RIF-resistant isolates, representing two
(10.5%) of the 19 RIF-resistant strains defined by RFLP analy-
sis, had a mutation in codon 513 of rpoB, while only one (2.4%)
of the isolates in the Western Turkey study was found to have
mutations at codon 513. In addition, some mutations that were
found in our study were not observed in the Western Turkey
study (e.g., mutation in codon 572 of the rpoB gene), and vice
versa (e.g., dual mutations at codons 515 and 533 of the rpoB
gene).
It was reported that GAC516GTC, CAC526TAC, and
TCG531TTG of the rpoB gene were found more often in iso-
lates from Asia, Australia, and Russia based on a review of 59
reports describing rpoB mutations found in about 3,000 isolates
from 44 different countries.21 In our study, the TCG531TTG
alteration was the most commonly observed mutation; however,
the GAC516GTC alteration was observed in only one of the
five isolates with mutations at codon 516 of rpoB. In one iso-
late, we observed a novel mutation (ATC572CTC) outside the
81-bp core region. Mutations at codon 516 of the rpoB gene
being the second most commonly observed might be of con-
siderable importance, as previous studies suggested that, in con-
trast to mutations at codon 531 and 526, which cause high level
resistance to all rifamycins, mutations at codons 511, 516, 519,
and 522 of rpoB result in a high level of resistance to RIF and
rifapentine, but susceptibility to rifabutin, rifalazil, and ben-
zoxazinorifamicin KRM-1648.19,26 Isolates susceptible to the
latter drugs may develop resistance through secondary muta-
tions in the rpoB gene.15 However, due to the limit of the re-
source, susceptibility to the other rifampin derivatives was not
tested in this study.
The prevalence of katG codon 315 mutation in INH-resis-
tant M. tuberculosis isolates varied from 26% to 93.6% in pre-
vious reports.5,10,12 Although the prevalence of katG codon 315
mutations observed in our study (63.0%) is within the range
reported previously, we observed a remarkable difference in
the proportion of isolates having a mutation at codon 315 of
the katG gene between the MDR isolate group (78.9%) and
the INH-mono-resistant isolate group (25%). This observation
may suggest that mutations at codon 315 of the katG gene have
a predictive value for MDR-TB. Future studies with samples
of a larger size are needed in order to further assess the im-
plications of this observation and provide a better understand-
ing of molecular basis of M. tuberculosis drug resistance in
Turkey.
The high correlation between DNA sequencing and AS-
PCR results suggests that AS-PCR is a reliable tool for rapid
screening for the genetic mutations associated with M. tu-
berculosis drug resistance with less resource and technique
demand as compared with DNA sequencing. The limitation
of the AS-PCR detection is that each assay only detects mu-
tations in a single codon. In order to improve the efficiency
of the allele-specific PCR detection, future efforts should be
directed to the development of multiplex allele-specific PCR
methods combining multiple targets’ detection in a single 
assay.
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